Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

470P - Genomic landscape and its correlations with immunotherapy-related biomarkers in Chinese colorectal cancer patients

Date

16 Sep 2021

Session

ePoster Display

Topics

Tumour Site

Colon and Rectal Cancer

Presenters

Xiao Zheng

Citation

Annals of Oncology (2021) 32 (suppl_5): S530-S582. 10.1016/annonc/annonc698

Authors

X. Zheng1, Y. Xiao2, S. Ding3, F. Pang2, R. Lin4, P. Luo5, Z. Yan3

Author affiliations

  • 1 Department Of General Surgery, Taian City Central Hospital, 000 - Tai'an City/CN
  • 2 Medical, Shanghai Topgen Biomedical Technology Co., Ltd., 200120 - Shanghai/CN
  • 3 Bioinformatics, Shanghai Topgen Biomedical Technology Co., Ltd., 200120 - Shanghai/CN
  • 4 Technology, Shanghai Topgen Biomedical Technology Co., Ltd., 200120 - Shanghai/CN
  • 5 Business, Shanghai Topgen Biomedical Technology Co., Ltd., 200120 - Shanghai/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 470P

Background

Colorectal cancer (CRC) accounts for high rates of morbidity and mortality among people with solid tumors worldwide. As traditional treatments are limited and often intolerant for patients with advanced CRC, immunotherapy could be a promising way. In order to explore the potential use of immunotherapy biomarkers, we aimed to assess gene alteration and its correlations with microsatellite instability (MSI), tumor mutation burden (TMB) and tumor neoantigens burden (TNB) in Chinese CRC populations.

Methods

133 samples were collected from May, 2020 to February, 2021. All specimens were detected by OncoDrug-Seq 603-gene panel assay through next generation sequencing (NGS) using Illumina NovaSeq 6000. TMB-H was set up as higher than 75% of total quantile, TNB-H was set up as higher than 80%, and TNB-L was defined as less than 50%. MSI was calculated by msisensor2 software (MSI-H was defined as score greater than 20%).

Results

There were three individuals who had MSI-H and the rest were MSS. 21 individuals had TMB-H and 112 patients had TMB-L. As for TNB level, 32 patients were TNB-H, 43 patients were TNB-M, and 58 patients were TNB-L. There were 179 altered genes among all 133 patients. The top five genes with mutational incidence were TP53 (68%), APC (64%), KRAS (53%), PIK3CA (15%), PTEN (8%). Among top five gene mutation, only one gene mutation was associated with TNB, which was KRAS (p=0.45). While, age and gender were not associated with MSI, TMB and TNB level in Chinese CRC patients. Mutational incidences of significant pathways (from KEGG database) were also analyzed. Six signaling pathways were related, including Wnt signaling pathway (68%), ERK signaling pathway (66%), PI3K -Akt signaling pathway (64%), RAS signaling pathway (53%), and TGFβ signaling pathway (7%).

Conclusions

The landscape of gene alteration and MSI, TMB and TNB among Chinese CRC populations in this study will further assist the utilization of these biomarkers to immunotherapy strategies.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.